• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    35393425.pdf
    Size:
    559.8Kb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Telli, M. L.
    Tolaney, S. M.
    Shapiro, G. I.
    Middleton, M.
    Lord, S. R.
    Arkenau, H. T.
    Tutt, A.
    Abramson, V.
    Dean, Emma J
    Haddad, T. C.
    Wesolowski, R.
    Ferrer-Playan, J.
    Goddemeier, T.
    Grombacher, T.
    Dong, J.
    Fleuranceau-Morel, P.
    Diaz-Padilla, I.
    Plummer, R.
    Show allShow less
    Affiliation
    Stanford University School of Medicine, Stanford, CA, USA
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recommended phase 2 dose of the combination of the ataxia-telangiectasia and Rad3-related (ATR) inhibitor berzosertib and cisplatin observed in patients with advanced solid tumors, including TNBC. Forty-seven patients aged ≥18 years with advanced TNBC received cisplatin (75 mg/m2; day 1) and berzosertib (140 mg/m2; days 2 and 9), in 21-day cycles. Berzosertib was well tolerated, with a similar toxicity profile to that reported previously for this combination. The overall response rate (90% confidence interval) was 23.4% (13.7, 35.8). No relevant associations were observed between response and gene alterations. Further studies combining ATR inhibitors with platinum compounds may be warranted in highly selected patient populations.
    Citation
    Telli ML, Tolaney SM, Shapiro GI, Middleton M, Lord SR, Arkenau HT, et al. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. Vol. 8, npj Breast Cancer. Springer Science and Business Media LLC; 2022.
    Journal
    NPJ Breast Cancer
    URI
    http://hdl.handle.net/10541/625270
    DOI
    10.1038/s41523-022-00406-0
    PubMed ID
    35393425
    Additional Links
    https://dx.doi.org/10.1038/s41523-022-00406-0
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1038/s41523-022-00406-0
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
    • Authors: Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA
    • Issue date: 2021 Aug
    • Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
    • Authors: Terranova N, Jansen M, Falk M, Hendriks BS
    • Issue date: 2021 Feb
    • Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    • Authors: Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S, Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF, Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil R
    • Issue date: 2018 Nov 6
    • Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.
    • Authors: Talele S, Zhang W, Burgenske DM, Kim M, Mohammad AS, Dragojevic S, Gupta SK, Bindra RS, Sarkaria JN, Elmquist WF
    • Issue date: 2021 Dec
    • Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
    • Authors: Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM
    • Issue date: 2016 Jun 15
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.